Corticosteroids in ophthalmology : drug delivery innovations, pharmacology, clinical applications, and future perspectives by Gaballa, Sherif A. et al.
1 
 
This is a post-peer-review, pre-copyedit version of an article published in Drug Delivery and Translational Research. The 
final authenticated version is available online at: https://doi.org/10.1007/s13346-020-00843-z   
2 
 
Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications and future 
perspectives 
 
Sherif A. Gaballa1, Uday B. Kompella2, Omar Elgarhy 1, Ali M Alqahtani 3, Barbara Pierscionek4, Raid G Alany5,6, Hamdy 
Abdelkader1,7* 
 
1 Department of Pharmaceutics, Faculty of Pharmacy, Mania University, Mania, Egypt, 2Departments of Pharmaceutical Sciences, Ophthalmology, 
and Bioengineering, University of Colorado Anschutz Medical Campus, Aurora, CO 80045 
 3 Department of Pharmacology, College of Pharmacy, King Khalid University, Abha-61441, Kingdom of Saudi Arabia, 4School of Life Science 
and Education, Staffordshire University, College Road, Stoke-on-Trent  ST4 2DE, UK 
5Drug Discovery, Delivery and Patient Care Theme, Faculty of Science, Engineering and Computing, Kingston University, Penrhyn Road, 
Kingston upon Thames, Surrey. KT1 2EE 
6School of Pharmacy, The University of Auckland, Auckland, New Zealand 
7Department of Pharmaceutics, Faculty of Pharmacy, Deraya University, Minia, Egypt 
Abstract  
Corticosteroids remain the mainstay of the treatment for various ocular conditions affecting the ocular surface, anterior and posterior segments of 
the eye due to their anti-inflammatory, anti-oedematous and anti-neovascularization properties. Prednisolone, prednisolone acetate, 
dexamethasone, triamcinolone acetonide, fluocinolone acetonide, and loteprednol etabonate are amongst the most widely used ophthalmic 
corticosteroids. Corticosteroids differ in their activity and potency in the eye due to their inherent pharmacological and pharmaceutical differences. 
Different routes and regimens are available for ocular administration of corticosteroids. Conventional topical application to the eye is the route of 
choice when targeting diseases affecting the ocular surface and anterior segment, while periocular, intravitreal, and suprachoroidal injections can 
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be potentially effective for posterior segment diseases. Corticosteroid-induced intraocular pressure elevation and cataract formation remain the 
most significant local risks following topical as well as systemic corticosteroid administration. Invasive drug administration via intracameral, 
subconjunctival and intravitreal injection can enhance ocular bioavailability and minimize dose and dosing frequency of administration, yet may 
exacerbate ocular side effects of corticosteroids. This review provides a critical appraisal of the ophthalmic uses of corticosteroid, routes of 
administration, drug delivery fundamentals and novel ocular implantable steroids delivery systems, factors influencing side effects and future 




Corticosteroids, eye diseases, ocular drug delivery, steroids intracanalicular inserts, ocular hypertension, cataract, delivery systems. 
 
Correspondence  
Hamdy Abdelkader, PhD, FHEA 






1.  Introduction………………………………………………………………………………………………….5 
2.  Corticosteroids: structure and physicochemical properties ...................... 7 
3.  Corticosteroids: pharmacotherapy .............................................................15 
4.  Routes of ocular corticosteroid administration and pharmacokinetics. ... 16 
4.1. Topical ocular administration…………………………………………………………………….17 
4.2. Systemic administration………………..………………………………………………………….. 22 
4.3. Periocular injection……………………………………………..……………………………………..23 
4.3.1. Subconjunctival injection…………………………………………………………………23 
4.3.2. Sub-Tenon injection………………………………………………………………………..25 
4.3.3. Retrobulbar injection……………………………………………………………………….25 
4.3.4. Peribulbar injection…………………………………………………………………………26 
4.4. Intraocular injection……………………………………………………………………………….…26 
4.4.1. Suprachoroidal injection……………………………………………………………….…27 
4.4.2. Intracameral route…………………………………………………………………………...28 
4.4.3. Intravitreal route………………………………………………………………………….….29 
5.  Ophthalmic adverse effects of glucocorticoids ………………….…35 
5.1. Corticosteroid-induced IOP elevation (ocular hypertension)………………………………………………………….36 
5.1.1. Mechanism of corticosteroid-induced IOP……………………..………..…37 
5.1.2. Factors affecting corticosteroid-induced IOP…………………………...38 
5 
 
5.2. Corticosteroid-induced cataract formation…………………………………………….43 
6.  Approaches to avoid and minimize corticosteroid-induced ocular complications……………………………………………………………………….…..46 







This review provides an in-depth discussion of ophthalmic corticosteroids including clinical uses, routes of administration, drug delivery 
fundamentals and delivery systems, factors influencing ocular side effects and future perspectives for drug delivery scientists, pharmacists, 
ophthalmologists and other health care professionals. 
Corticosteroids are amongst the most potent and effective anti-inflammatory medications. Consequently, corticosteroids are widely prescribed for 
the management of various ocular diseases, which can be classified into two main groups (Figure 1). Diseases affecting the anterior segment of 
the eye including inflammation caused by surgery, injury, or other conditions, eye swelling, redness, itching, and pain, conjunctivitis [1], uveitis 
[2], dry eye [3], scleritis and episcleritis [4] and those affecting the posterior segment of the eye  including non-infectious posterior segment uveitis, 
macular edema following branched/central retinal vein occlusion, diabetic macular edema (DME) in patients post-cataract surgery [5, 6], DME in 
patients who have a history of intraocular pressure (IOP) elevation following corticosteroid dosing, diabetic retinopathy  (DR) [7], , age-related 
macular degeneration (AMD) [8] and postoperative macular edema [9].  
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Dexamethasone, difluprednate, fluocinolone acetonide, fluorometholone, loteprednol etabonate, prednisolone, prednisolone acetate and 
triamcinolone acetonide are the key corticosteroids for ophthalmic use. They can be administered through topical, systemic, periocular and 
intraocular routes to treat eye diseases.  Corticosteroids are available in a variety of dosage forms including solutions, suspensions, emulsions, 
ointments and slow-release implants for use based on the targeted disease and its location inside the eye.  
The anti-inflammatory effect of corticosteroids is primarily a result of the modulation of gene expression by transrepression and upregulation 
following their binding to the cytosolic glucocorticoid receptor. The therapeutic effects of corticosteroids will be discussed in detail later in section 
3. Corticosteroids exert anti-neovascular effects and inhibit the formation of new blood vessels. These effects may be significant for treating AMD 
and DR [10-12]. Corticosteroids are considered superior anti-inflammatory drugs for treating ocular inflammations due to their potency and 
efficacy [13] and they  may be a more appropriate treatment alternative for anti-vascular endothelial growth factor (anti-VEGF) agents especially 
in DME patients awaiting cataract surgery  or in pseudophakes [10]. However, corticosteroids are not devoid of serious ocular side effects such as 











Figure 1 Various ocular surface, anterior and posterior eye diseases that can be treated with corticosteroids. 
 
2. Corticosteroids: structure and physicochemical properties  
 
All corticosteroids share a basic sterane (steroid nucleus) structure with 21 carbon atoms and four rings. Figure 2 shows the chemical structures of 
commonly used ophthalmic corticosteroids. Structural modifications produce new compounds with different physicochemical properties and 
biological potencies [17]. Table 1 outlines the physicochemical properties, log partition coefficient (P), novel ophthalmic formulations, and the 
commercially available dosage forms of commonly used corticosteroids for the treatment of ophthalmic diseases.  
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Most corticosteroids with anti-inflammatory properties are characterized by the presence of hydroxyl groups at C17 in α- position, a double bond 
between C4 and C5, a ketone group at C3 and an oxygen functional group at C11 [18, 19]. With the addition of double bonds between C1 and C2, 
such as those present in prednisolone, there is a decrease in degradation rate. Further, the addition of a fluorine atom at C9  led to enhanced anti-
inflammatory activity as is the case with triamcinolone [18]. The presence of furoate ester moiety in C-17 α position increases the affinity of 
corticosteroids to the glucocorticoid receptor. Fluticasone furoate and mometasone furoate are examples of highly potent corticosteroids with the 
lipophilic  moiety [20, 21].  
Further, replacement of the hydroxyl group at the C21 in prednisolone with an acetate group resulted in the formation of the prodrug prednisolone 
acetate. The acetate form of prednisolone is more lipophilic and showed enhanced corneal permeation compared to prednisolone and its phosphate 
form [22]. Also, the presence of acetonide group at C16 and C17 leads to increased lipophilicity for triamcinolone acetonide and fluocinolone 
acetonide.  
Majority of ophthalmic products are solutions. However, corticosteroids are marketed as solutions, suspensions, emulsions and implants for 
ophthalmic use, with the majority of the products being more complex than simple aqueous solutions. This is because corticosteroids typically 
have low water solubility. Thakur et al. [23] studied the solubility of corticosteroids in phosphate buffer saline containing 0.5 % w/v carboxymethyl 
cellulose. The  solubility of the studied corticosteroids was in the following order: prednisolone (0.243 mg/ml > dexamethasone (0.16 mg/ml > 
fluocinolone acetonide (0.05 mg/ml) > triamcinolone acetonide (0.021 mg/ml)  [23]. The water solubility of fluocinolone acetonide was found to 
be only 4% that for dexamethasone, due to the presence of the acetonide group [24, 25]. In addition, the presence of phosphate moiety at C21 
allows the formation of sodium salts of corticosteroids with improved water solubility. Corticosteroids can be broadly divided into water-soluble 
and poorly water-soluble. Dexamethasone sodium phosphate and prednisolone sodium phosphate are two examples of water soluble 
corticosteroids[26, 27]. Poorly water-soluble corticosteroids include prednisolone, prednisolone acetate, triamcinolone acetonide and fluocinolone 
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acetonide. Water soluble corticosteroid forms can be formulated as ophthalmic solutions for use as eye drops. Poorly soluble forms are generally 
administered as ophthalmic suspensions or emulsions (Table 1). Due to the presence of hydroxyl groups at X17 and R21 positions, dexamethasone 












Interestingly, corticosteroids with low solubility are the drugs of choice for polymeric slow-release delivery systems such as Ozurdex® 
(Dexamethasone-based implant) and Iluvien® (fluocinolone acetonide-based implant) [28]. Ozurdex® (a bio-erodible implant) is recommended for 
intravitreal injection every 6 months; Iluvien® (a non-bioerodible implant) is injected every 36 months. This marked long duration of action of 
Iluvien® has been partly ascribed to the lower solubility of fluocinolone acetonide compared to dexamethasone, in addition to the non-degradable 
polymer and slower zero-order release rate for fluocinolone acetonide [29, 30].    
e Intravitreal injection of triamcinolone acetonide is an effective treatment for various ocular inflammatory diseases. Kenalog®-40 injection 
manufactured by Bristol Myers Squibb, has not been approved for intraocular use and its use in ophthalmology has been off-label [31]. This 
injectable dosage form, when administered intraocularly, has resulted in rare cases (yet clinically significant) of non-bacterial endophthalmitis 
(around 1%), which was linked to the presence of inadequate excipients for intraocular administration such as benzyl alcohol (a preservative). 
Benzyl alcohol is suspected of being an irritant [32, 33]. Hence, Kenalog®-40 is not indicated for intraocular administration by the European Union 
[34].  Preservative-free Triesence® and Trivaris®, two ophthalmic suspensions of triamcinolone acetonide were developed and approved for 
intravitreal injections (Table 3) [30].  
 
The natural logarithm of octanol-water partition coefficient (Log P) is a useful physicochemical parameter that represents drug lipophilicity and 
drug affinity for biological membranes including corneal epithelium. Table 1 shows log P values of corticosteroids commonly used in 
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ophthalmology. Log P varies according to the functional group substitution of the corticosteroids and ionization state. Esters such as prednisolone 
acetate (log P = 2.4) are more lipophilic than the parent weak acid  (prednisolone, log P = 1.6) [35, 36]. On the other hand, phosphate salts s such 
as dexamethasone sodium phosphate (log P 1.5) are more hydrophilic compared to the parent drug (log P 1.83) as shown in Table 1. Dexamethasone 
sodium phosphate and prednisolone sodium phosphate, in their ionized form, showed less corneal permeation compared to their weak acids 
counterparts (dexamethasone and prednisolone) when administered as eye drops. Advanced drug delivery systems such as niosomes and liposomes 
of these sodium salts have demonstrated enhanced corneal permeation compared with the control solutions of the corticosteroid sodium salts  [26, 
37]. 























Practically water in 
soluble (0.16 mg/ml) 
[38] with a higher 
affinity to glucocorticoid 
receptor [39]. Its 
aqueous humor t1/2 is 
about  (3-6) h [40] and 
requires frequent 
administration. 













Synthetic sodium salt of 
dexamethasone 
phosphate, which is 
highly water-soluble 
(1.52 mg/ml) [26], 
hydrolyzed into 
dexamethasone, with 
poor corneal penetration 
(ionized form) and used 
mainly for anterior 
segment inflammation in 
novel delivery systems 
to improve corneal 
permeability [26, 27, 
44]. 
 
1.5 [36] Liposome [26]. 















commonly used in 
acetate and phosphate 
form [47]. Very slightly 
soluble (0.243 mg/ml at 
25 C) in water [41, 48]. 
1.6 [41, 49] Niosomes [50]. 
Nanoparticle-laden 
contact lenses [47]. 
Nanocapsules [51]. 









prodrug, which is 
hydrolyzed to 
prednisolone (active 
form). It is practically 
insoluble in water. It has 
higher corneal 
permeability, less potent 
than dexamethasone [52, 
53]. 
2.4 [54] Niosomes [50]. 
Eye drop [55]. 
Liposomes [56]. 
Hydrogel contact lenses 
[57] 
 Kapimox-P  suspension 








Sodium phosphate salt  
of prednisolone with 
lower corneal 
penetration capability 
than acetate salt (ionized 
form) [27]. It is freely 
soluble in water (soluble 
1 in 3 in water), and 
mostly formulated as 
solution [41]. 
1.15 [36]  
Niosomes [50]. 
Gel 1% [58]. 







A corticosteroid with a 
fluorine atom in the 
ninth position. It is very 
slightly soluble in water 
triamcinolone acetonide 
(21 µg/ml) [59]and more 
potent than 
triamcinolone [60]. It 
remains in  the vitreous 
for much longer than 
other corticosteroids and 
formulated as an 
intravitreal implant [61].  













A corticosteroid with 
fluorine instead of a 
hydrogen atom in the 
sixth and ninth positions.  
It is highly lipophilic and 
practically insoluble in 
water (0.05 mg/ml) [63, 
64]. Assessed as an 
intravitreal implant [65] 
and marketed as an 
intravitreal suspension. 
2.5 [36]   
Intravitreal implant [66] 
Liposomes [67] 
 







Diester bond at C17 with 
increased lipophilicity 
(water solubility 0.5 
µg/ml) and higher 
corneal penetration [68]. 
It is hydrolyzed in 
cornea and aqueous 
humor into its active 
form with lower side 
effects [69].  
3.04 [68]  
Gel 0.5 % [70]. 




Fluorometholone Synthetic fluorinated 
corticosteroids with 
acetate group at C17.  
Practically water 
insoluble (0.03 mg/ml) 
[72]. 
2.0 [36]. Polymeric Micelle eye 
drop[72] 
Suspension 0.1% [73] 
Flucon® suspension 
FML® ointment 
Difluprednate It is a butyrate ester of 
difluoro prednisolone 
acetate which is rapidly 
deacetylated in the 




lipophilic due to the 
presence of butyrate and 
acetate moieties [74]. 
Practically water 
insoluble (0.01 mg/ml) 
[75].  













3. Corticosteroids: brief overview of pharmacology with emphasis 
on inflammatory conditions of eye 
Ocular inflammation, if untreated,  could lead to temporary or permanent vision loss 
and involves local modification in blood flow and an attack on ocular tissue by immune 
cells and different inflammatory mediators [77, 78].Common clinical signs and 
symptoms include such as redness, itching, pain and swelling [79].  
Corticosteroids have been used for treating ocular inflammation for around five 
decades, since the systemic administration of an adrenocorticotrophic hormone derived 
from the hypophyseal system led to a considerable outcome improvement in patients 
with uveitis [80]. They exert their anti-inflammatory effects by blocking the cascading 
inflammatory mechanisms including the biosynthesis of eicosanoid; the release and 
activity of cytokines, chemotactic proteins and matrix metalloproteinases [81]; and 
accumulation of inflammatory proteins such as vascular endothelial growth factor 
(VEGF) and cyclooxygenase 2 by decreasing the stability of their mRNA [82]. 
Corticosteroids exert anti-inflammatory activities via genomic and nongenomic effects 
[19, 82]. 
 
The genomic mechanism produces effects through glucocorticoid receptors (GR). 
Within the cytosol; corticosteroids bind with high affinity to the GR and the active 
corticosteroid-GR complex translocates into the nucleus. Herein, genomic effects 
involve the up-regulation of anti-inflammatory proteins expression such as lipocortin-
1 and interleukin-10 and suppression of the expression of proinflammatory proteins 
such as nuclear factor-kappa-B (NF-kappa-B) and activator protein-1 (AP-1). The non-
genomic mechanism exerts rapid effects on immune cells and regulate cell 
adhesion;[83] and involves the inhibition of dilatation of the blood vessels, vascular 
permeability and leukocyte migration [82, 84] through the inhibition of phospholipase 
A2.  Generation of novel corticosteroids that exert their effect solely through the non-
genomic pathway has potential  for future research [85] and is discussed further  in this 
review.  
The detailed mechanisms by which corticosteroids benefit AMD and DME are still 
being elucidated and an anti-neovascularization mechanism has been proposed [11]. 
Corticosteroids can stabilize and reconstitute the blood-retinal barrier, positively 
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impacting  Starling’s equilibrium by capillary constriction and VEGF downregulation 
[86]. Ayalasomayajula et al. [12] showed that fluocinolone acetonide inhibits the 
expression of VEGF in RPE cells through glucocorticoid receptors and also inhibits the 







4. Routes of ocular corticosteroid administration and 
pharmacokinetics. 
Different drug delivery routes have been employed for the management of ocular 
conditions depending on the disease site. Drugs with high corneal permeability and 
drug products with prolonged precorneal retention are useful in improving 
bioavailability of the ocular surface and anterior segment [87]. Generally, topical drug 
delivery is most suitable for localizing drug effects and minimizing systemic adverse 
effects for diseases of the anterior eye [88]. For diseases affecting the posterior segment, 
different strategies have been employed to increase or prolong drug efficacy. These 
include intraocular injections to localize the drug in the posterior of the  eye and 
administration in implant form sustains the drug release and prolongs the duration of 
therapy [89]. Systemic administration may also be used to reach the target- tissues in 
the posterior segment of the eye via the systemic circulation [90].  
Generally, ocular drug delivery of corticosteroids can be achieved via different routes 
as illustrated in Figure 3. Key routes of administration and the associated drug 














Figure 3 Routes of administration for ocular delivery of corticosteroids. 
 
4.1. Topical ocular administration 
Topical application is most favored route for ocular drug delivery, especially when 
targeting diseases affecting the ocular surface and anterior segment of the eye. It is 
accomplished by directly applying  drug formulations on the ocular surface (Figure 3) 
[91].  It is non-invasive with reasonable patient adherence. Topical administration is 
likely to minimize the systemic side effects and allows the use of a relatively high drug 
concentration sufficiently close to the affected ocular tissue compared to  systemic 
administration [17, 92]. For topical ocular delivery of corticosteroids, many 
conventional formulations including  aqueous eye drop formulations such as  simple 
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solutions, suspensions, gels and emulsions as well as ointments have been employed 
[93, 94].. However, the major drawback of these conventional liquid formulations is 
the limited ocular bioavailability [95, 96]. This could be attributed to multiple 
physiological barriers including epithelial and connective tissue barriers, tear turnover, 
nasolacrimal drainage of the instilled dose and potentially poor in vivo dissolution of 
practically insoluble corticosteroids (Table 1) [91, 97, 98]. Nasolacrimal drainage and 
systemic absorption via the nose, GI tract and the conjunctival blood vessels are the 
main reasons for induced systemic toxicity of topically applied ophthalmic medications 
[99-101].  
Drug lipophilicity can contribute to the extent of systemic drug absorption after topical 
instillation of ophthalmic eye drops. The contribution of nasolacrimal pathway to 
systemic drug absorption has been reported to decrease with increasing lipophilicity of 
drug [101]. Ophthalmic ointments or viscous gels are also available for topical 
administration of corticosteroids such as fluorometholone, dexamethasone and 
loteprednol etabonate. While these formulations reduce drug drainage from the eye 
surface, they cause transient blurring of vision and matted eye lids. Other formulations 
factors that are likely to affect ocular bioavailability of water-insoluble forms of 
corticosteroids include particle size and viscosity of the vehicle. These two key factors 
are likely to have an impact on in vivo dissolution time and drug loss from the surface 
of the eye through the nasolacrimal drainage system. 
More recently, the effects of particle size and viscosity on the area under the aqueous 
humor concentration-time curve (AUC0-24h) were investigated as a measure of ocular 
bioavailability, of three budesonide suspension formulations. The three suspension 
formulations were all isotonic but formulated with low (4 cP) and high (50 cP) viscosity 
values, and different particle sizes (nanosize versus micorsize particles). The AUC0-24h 
values were 1.064, 1.013 and 1.630 for NP-LV (particle size: 0.71 µm and viscosity: 
4.89 Pc), MP-LV (particle size: 1.95 µm and viscosity: 4.92 cP) and MP-HV (particle 
size: 1.98 µm and viscosity: 53 cP). These results indicate that the viscosity rather than 
particle size has a more pronounced effect on the ocular bioavailability of budesonide. 
Precorneal residence time and retention of the formulation on the surface of the eye is 
more important than particle size.  Formulation of  corticosteroids as microsuspensions 
with high-viscosity resulted in   more ocular bioavailability than their low-viscosity 
counterpart [102].On the other hand, topical corticosteroid administration could 
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develop faster (few hours to several days) ocular adverse effects especially a rise in IOP 
compared with other routes of administration, such as systemic and inhaled 
corticosteroids which could take months to years to develop an appreciable rise in IOP 
[103-105]. For example, it has been reported that topical administration of 
corticosteroids for 4-6 weeks can result in elevation of IOP > 16 mmHg in 5% and 
between 6-15 mmHg in 30% of the treated population [105]. The typical pulsatile (high 
local concentration and repeated instillations on the surface of the eye) mode of 
administration of conventional corticosteroids suspensions and eye drops could be the 
major contributing factor of this serious adverse effect [106]. The effect of different 
routes of administration of corticosteroids on elevation of IOP will be discussed later 
in more detail [105]. 
Furthermore, topically applied corticosteroids are unlikely to attain therapeutic drug 
concentrations in the back of the eye and are therefore not the best option for  treatment 
of vitreoretinal conditions [106, 107]. Nonetheless, corticosteroid difluprednate 
ophthalmic drops have been suggested as candidates for  reducing macular oedema in 
children [108].  Most recently, we have reported that topically administered 
beclomethasone dipropionate loaded cubosomes markedly improve the endotoxin-
induced uveitis in the rabbit model. Results also proved that the lipophilic 
beclomethasone dipropionate  penetrated ocular tissue and significantly reduced  
inflammation induced in the retina [109].  
 
The intraocular anti-inflammatory effect of a topically applied corticosteroid not only 
depends on its potency but also on its metabolic stability and elimination and its ability 
to penetrate multiple physiological barriers [110]. Various advanced ophthalmic 
formulations for corticosteroids including nanosuspension, nanoemulsions, 
microemulsions [43], liposomes [111], niosomes [50] and cubosomes [39, 112] have 
been developed to overcome the limitations of conventional solutions and suspensions 
of corticosteroids. These novel formulations could serve as potential alternatives for 
conventional ophthalmic pharmaceuticals. This is because of their improved ocular 
availability and/or tolerability as they provide controlled or sustained drug release 
[106].  For example, topical administration of prednisolone acetate 1% micro-
suspension increased the intraocular concentration of prednisolone acetate up to 20-
fold. Li Gan et al  [39] reported that  the Papp values were 2.16×10−6 and 0.48×10−6 cm/s 
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for dexamethasone-cubosomes and dexamethasone-Na phosphate eye drops, 
respectively. These results indicated a 4.5-fold increases in dexamethasone corneal 
penetration with cubosomes [39]. Moreover, the ocular bioavailability of prednisolone 
acetate and prednisolone sodium phosphate loaded into nano-sized ethoniosomes was 
1.54- and 1.75-fold higher than that for the conventional suspension and solution eye 
drops containing prednisolone acetate and prednisolone sodium phosphate, respectively 
[50]. 
Table 2 shows more examples of lipid-/surfactant-based vesicles that markedly 
improved ocular bioavailability and apparent permeability coefficient (Papp) of 
corticosteroids such as dexamethasone and prednisolone. These results demonstrated 
the beneficial role of the lipid-based nanosized systems, including, niosomes, 
ethoniosomes, liposomes and cubosomes in enhancing corneal delivery of 
corticosteroids compared with the conventional dosage form. These novel delivery 
systems may increase  ocular bioavailability, prolong drug action, and  decrease  side 
effects in the anterior eye with enhanced ocular biocompatibility and tolerability [39, 
113]. 
However, the therapeutic effect of topically applied corticosteroids requires penetration 
of the applied drug through the ocular surface barriers including precorneal tear film, 
cornea, and/or conjunctiva/sclera. The cornea, which represents the greatest barrier for 
intraocular penetration, has lipophilic and hydrophilic regions, requiring drugs with an 
optimal log P or lipophilicity-hydrophilicity balance [114]. The cornea is less 
permeable to more polar and hydrophilic corticosteroids such as sodium salts of 
corticosteroid phosphate [115, 116] compared to the alcoholic and acetate derivatives 
of dexamethasone and prednisolone that are more lipophilic [117, 118].  
The concentration of prednisolone was determined in human aqueous humor after 
topical administration of 50 µl of prednisolone acetate (1%) and prednisolone sodium 
phosphate (0.5%).  Unsurprisingly, the mean peak concentration of prednisolone in 
aqueous humor after two hours of the topical application was 669 ng/ml and 25.6 ng/ml 
for prednisolone acetate and prednisolone sodium phosphate, respectively. These 
results  reflected a 26-fold  higher corneal penetration of the lipophilic prednisolone 
acetate compared to the polar prednisolone phosphate [119]. 
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The addition of cyclodextrins resulted in enhancement of both solubility, corneal 
permeability and ocular bioavailability of dexamethasone compared with commercially 
available dexamethasone alcohol (0.1%) solution  [120]. However, the enhanced 
corticosteroid ocular bioavailability can result in a significant elevation of IOP and 
increased sensitivity to eye infections, such as those caused by  herpes simplex virus 
[16, 121].  
 
Table 2 Lipid-based systems for ocular delivery of selected corticosteroids and their 





Ocular pharmacokinetics  Reference 
Cubosomes  Beclomethasone 
dipropionate 
Cubosomes increased the Papp by 3.8-fold compared to the 
control suspension. The precorneal residence time and the 
AUC increased by 8.5- and 5.5-fold, respectively, compared 
to the control sodium fluorescein solution. The ocular 
bioavailability of the loaded drug was 5.52 compared to the 
suspension form. 
[109] 
Cubosomes Dexamethasone -and 1.8 -and the AUC by 4.5app the P dCubosomes increase




Ethoniosomes enhanced the ocular bioavailability (AUC) by 




Liposomes showed 2.3-time reduction in the pro-
inflammatory cytokine interleukin 6 (IL-6) concentration 





Liposomes increased the AUC compared to control solution. 
Also, they markedly reduced the inflammatory signs of 
uveitis compared to the solution dosage form, indicating 






Niosomal in situ-gel increased AUC and Papp, value by 1.75-
and 2.82-fold, respectively, compared to the control pure drug 
solution. 
The Tmax increased from 1 h for solution to 2 h for the 






4.2. Systemic administration 
The systemic administration of corticosteroids had been widely used in ocular clinical 
practice for controlling ocular inflammatory disorders since the 1950s [125]. It has been 
indicated as a potential alternative to the topical application for the treatment of diseases 
of the posterior segment of the eye [126, 127]. Systemic corticosteroids, especially oral 
corticosteroids, may show higher patient compliance. However, the blood-retinal 
barrier and blood-aqueous barrier remain could hinder drug access into the posterior 
and anterior segments [128, 129]. As such, ocular bioavailability following systemic 
administration of corticosteroids is low, thus, higher dose administration is needed 
[130, 131]. As a result, severe ocular side effects could be triggered including steroid-
induced IOP elevation, cataract formation, and recurrence of herpes simplex infection 
[16, 132, 133].  In addition, it may lead to serious acute and chronic systemic side 
effects throughout the body including osteoporosis [134, 135], immunosuppression, 
Cushing's syndrome [136, 137], adrenal suppression [138] and elevated blood pressure 
[132, 139].  
It has been reported that a single intravenous injection of prednisolone (500 mg) 
resulted in  50% of the steroidal concentration in the aqueous humor produced by 
topical administration of  four drops of methylprednisolone 0.5% eye drop [88, 140].  
Also, Hyndiuk et al. [141] demonstrated that the systemic administration  (via the 
intramuscular route) of methylprednisolone in monkeys resulted (at two days after 
injection)  in ocular corticosteroid concentration that was  less than 1% of what was 
achieved by periocular injection of an equal dose [141]. These findings further indicate 
the limited ocular bioavailability of systemically administered corticosteroids.  
The transport of drugs across the blood-ocular barrier is controlled by drug 
characteristics where  it is more permeable to lipophilic substances with high oil/water 
partition coefficients [142]. Radiographic localization study of dexamethasone 
following systemic administration revealed that it penetrated the choroid, retina and 
sclera, which may be attributed to its lipophilic nature [143-145]. Interestingly, 
systemic corticosteroids have been approved for treatment of various ophthalmic 
conditions. For instance, oral prednisolone is approved for ocular adnexal IgG4-related 
disease [146]. The intravenous methylprednisolone administration has been 
recommended in case of severe uveitis when rapid control of the inflammation is 
required [147].  Keratoplasty (corneal transplant) rejections and chronic bilateral uveitis 
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are better treated with systemic corticosteroids (prednisolone 1mg/kg/day) than other 
routes of administration [148].  
 
4.3. Periocular injection 
Periocular refers to the area that surrounds the eye globe and the periocular route 
provides local drug delivery to spaces directly surrounding the eye, adjacent to the 
sclera [149].  The injected drug crosses the sclera through passive diffusion and hence, 
the molecular weight of the administered drug is the rate-limiting step [150]. The 
Periocular injections include drug administration via the subconjunctival, sub-Tenon, 
peribulbar, and retrobulbar regions (Figure 3)  [151]. For posterior eye diseases, 
especially for diseases affecting the outer ocular layers, periocular administration has 
been considered as a useful route [152]. Owing to the porous nature and the huge scleral 
surface area (16.3 cm2), the periocular route can deliver substances with high molecular 
weight to the posterior segment of the eye [153]. Studies have  reported that the 
relatively porous scleral membrane, compared to cornea, is permeable to larger 
molecules such as therapeutic proteins up to 150 KDa molecular weight [154, 155]. 
Therefore, the transscleral periocular drug delivery provides  an option for  delivery of 
large hydrophilic molecules which is facilitated by  the increased surface area and high 
permeability of the sclera relative to cornea  [152].   
The lipophilicity of drug molecules can also influence their scleral permeation Studies 
looking at the correlation between drug lipophilicity and human scleral permeation 
showed that molecules with higher lipophilicity exhibited stronger binding to the sclera 
and thus, a longer transport time across the tissue [156]. 
Additionally, this route is commonly used for anesthesia before ocular surgery [152]. 
Depending on the drug characteristics , the administered drug can reach the vitreous 
and other intraocular tissues within 20-30 minutes following administration [157]. 
While periocular administration is considered to be less invasive than intravitreal 
injection,  periocular corticosteroid administration has complications including 
elevation of IOP, cataract formation and corneal decompensation [158, 159]. Also, it 
has been accompanied by atrophy of the orbital rim fat [160].  
4.3.1. Subconjunctival injection 
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When administered via the subconjunctival route, the drug is placed below the 
conjunctiva, where it penetrates directly, by diffusion, through the sclera, bypassing the 
conjunctival barrier which limits the bioavailability of topically instilled drugs (Figure 
3) [92]. Through the subconjunctival route, up to 500 µl could be injected and the drug 
substance could be delivered to both the posterior and anterior segments. Experimental 
evidence on dexamethasone  revealed that the concentration after subconjunctival 
injection was 12 times more than that of oral administration [161, 162].  
Kompella et al. [163] successfully prepared budesonide loaded polylactide (PLA) nano 
and microparticles. After subconjunctival injection in a rat model, this system 
effectively sustains the concentration of budesonide in the retina compared to a solution 
form. In rats treated with budesonide-loaded PLA nanoparticles, the retinal 
concentration of budesonide was nine-fold higher compared with the group treated with 
budesonide solution. Additionally, this study showed that budesonide decreases VEGF 
expression in retinal pigment epithelial cells via the glucocorticoid receptor activity 
[163]. Weijtens et al. [161] measured the concentration of dexamethasone in the human 
subretinal fluid after an oral dose of 7.5 mg dexamethasone and subconjunctival 
injection of 2.5 mg of dexamethasone sodium phosphate. The findings revealed a 28.7- 
fold higher concentration of dexamethasone in the subretinal fluid following the 
subconjunctival injection compared to the oral administration [161].  
However, the subconjunctival corticosteroid injection may be less effective than topical 
administration in the treatment of inflammation of the ocular surface [164]. After 
subconjunctival injection s, most of the injected corticosteroid is believed to leak back 
to the ocular surface through the needle tract reducing the injected drug depot [165, 
166]. Additionally, some of the injected drugs are systemically absorbed via the 
conjunctival and episcleral blood supply, which may affect the ocular surface 
bioavailability of subconjunctivally injected drugs [162, 167]. The local depot effect of 
injected corticosteroids makes them potentially helpful in prolonging the release of 
effective concentrations to the cornea, conjunctiva, sclera, choroid and retina [168]. 
Generally, parenteral corticosteroid solutions are well tolerated when injected 
subconjunctivally [169].  
The effect of the subconjunctivally injected suspensions of dexamethasone (1 mg) is 
believed to last for 1 to 2 days. However, triamcinolone acetonide (3 mg) lasted for up 
to 21 days. This can be attributed to the more inherent sustained release characteristics 
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(slower dissolution rate) of triamcinolone acetonide due to it being more lipophilic and 
less water soluble  than dexamethasone (Table 1) [169]. The subconjunctival injections 
were associated with some ocular side effects such as ocular pain, retinal detachment, 
globe perforation [170]  and formation of granuloma at the injection site [159, 171].  
 
4.3.2. Sub-Tenon injection 
The sub-Tenon injection involves drug injection into the sub-Tenon´s space (the space 
located between the sclera and the capsule) (Figure 3) [107, 172]. Sub-Tenon 
corticosteroid injections have been used for the treatment of various ocular 
inflammatory conditions. It is most commonly used for local administration of 
anesthesia during ocular surgery. This route is also used for corticosteroid delivery to 
the posterior segment of the eye [152]. 
The sub-Tenon injection of triamcinolone acetonide has been effectively used in the 
treatment of patients with macular edema and posterior uveitis. In one study, an increase 
in the IOP was observed in 2.17 % of  507 treated eyes [173, 174].  Cardillo et al.  [175] 
compared the efficacy of sub-Tenon injection of triamcinolone acetonide with that of 
the intravitreal injection in the treatment of macular oedema in human eyes. After a 1-
month follow up, they revealed that the intravitreally injected triamcinolone acetonide 
(4-mg) significantly decreased the macular thickness, which was greater than that 
produced by sub-Tenon injection of triamcinolone acetonide (40-mg) [175].   
In another study, the posterior sub-Tenon injection of triamcinolone acetonide was used 
for macular edema treatment in patients with average macular thickness above 300 µm 
and who did not respond to intravitreal injection of the anti-VEGF bevacizumab. The 
sub-Tenon injection of triamcinolone acetonide (20 mg) was found to effectively inhibit 
VEGF and reduce the average macular thickness from 476 µm to 368 µm after 2-
months treatment. No serious complications were reported [176]. 
 
4.3.3.  Retrobulbar injection 
Retrobulbar injection involves the injection of the drug into the conical section within 
the borders of the rectus muscles and their intramuscular septa and the drug injected 
within the muscle cone behind the globe of the eye (Figure 3) [177].  Retrobulbar 
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injection is advocated for posterior segment drug delivery to attain high drug 
concentration in the posterior tissue and avoid the systemic toxicity. This route is 
commonly used for anesthesia during ocular surgery where up to 5 ml could be injected 
[151].  For corticosteroid administration, the systemic and retrobulbar injection of 0.3 
ml suspension of tritiated 6-methyl-prednisolone acetate in monkey showed a higher 
drug concentration in the posterior tissue (retina) after two days (drug persisted for nine 
days when assayed) following retrobulbar administration. However, no drug was 
detected on days 2 and 9 after intramuscular injection. This indicated that 
corticosteroids could penetrate and last longer in monkey ocular tissue after retrobulbar 
injection compared with systemic intramuscular injection [141]. However, this route of 
ocular injection increases the risk of optic nerve trauma; consequently, the needle 
should not penetrate further than 1.5 cm behind the globe [151]. 
 
4.3.4. Peribulbar injection 
Unlike the retrobulbar injection, for peribulbar injection, the muscle cone is not 
involved and the drug is injected externally to the rectus muscles and their 
intramuscular septa (Figure 3) [178]. Up to 10 ml of drug formulation could be injected 
through peribulbar route depending on patient comfort and the speed of injection [151]. 
Anesthesia through the peribulbar injection is considered less effective than the 
retrobulbar route but is still used in case of complicated ocular surgery [152]. However, 
globe perforation is a risk , commonly associated with peribulbar injection where 
special care should be taken to ensure the needle is in the correct position [151]. 
Furthermore, this route is more likely to elevate IOP  compared with the retrobulbar 
injection [152]. Despite the benefits of periocular corticosteroid administration, there is 
a high risk of development of systemic adverse effects, hemorrhage, hyperemia and the 
possibility of conjunctival irritation in addition to patient compliance challenges [23, 
151].   
 
4.4. Intraocular injection 
Intraocular injection involves direct localization of corticosteroids intraocularly, 
bypassing ocular barriers related to both topical and systemic administration (Figure 3). 
Although intraocular injections are more helpful for local treatment of several ocular 
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diseases, there are many potential complications that are divided into corticosteroid- 
and injection-related unwanted effects. The most common corticosteroid-related  side 
effects are cataract, IOP elevation, increased infection potential and reduced wound 
healing [179, 180]. Injection-related adverse effects include pain, increased risk of 
globe perforation, vitreous hemorrhage, retinal detachment, bacterial endophthalmitis, 
and non-infectious endophthalmitis [181-183]. Intraocular injections in the clinic or 
developmental stages include intracameral, intravitreal and suprachoroidal injections. 
 
4.4.1. Suprachoroidal injection 
A recent approach to overcome the ocular barriers related to topical administration and 
target the posterior eye segment is via drug administration to the suprachoroidal space 
(SCS) [184]. This localized ocular drug delivery approach allows targeted delivery to 
the choroid and retina, away from the anterior segment (Figure 3) [185, 186].   
SCS drug administration is currently undergoing late-stage clinical evaluation. It is 
anticipated that a well-developed formulation injected into the SCS spreads quickly, 
exposing the drug to a wide region of the choroid-retina interface, thereby allowing 
drug transit into the choroid and the retinal layers [187].  However, this injection site 
allows a rather limited volume (200 µl) to be injected and if the injected volume is 
exceeded, it might lead to choroidal edema or choroidal detachment [188, 189]. Drugs 
injected in the SCS preferentially target tissues of the back of the eye, relative to the 
anterior chamber, cornea or conjunctiva. Therefore, a decrease in corticosteroid 
associated adverse effects, such as IOP elevation and cataract formation can be 
anticipated, [188]. XIPERE™ is triamcinolone acetonide suspension intended for 
suprachoroidal injection and is currently under marketing approval and 
commercialization in USA, UK and Australasia for treatment of macular edema 
associated with uveitis [190]. 
In the rabbit model, the suprachoroidal injection of triamcinolone acetonide suspension 
resulted in high triamcinolone acetonide concentrations in sclera, choroid, and retina. 
However, it was not detected in the aqueous humor [191]. This unique drug distribution 
may reduce the corticosteroid-induced ocular side effect [192]. A human clinical study 
was performed by Goldstein et al. [192] in the USA. They elucidated that a single 
suprachoroidal injection of triamcinolone acetonide was tolerable for the treatment of 
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noninfectious uveitis. Only ocular pain at the time of injection was noted, with no IOP 
elevation or systemic side effects [192].  
Currently, clinical trials are underway for dosing SCS using microneedles. These 
provided a minimally invasive approach for drug delivery and did not result in 
hemorrhage and retinal detachment [193, 194]. Moreover, the actual site of injection 
completely sealed  an hour after injection  [194]. Gilger et al. [195] studied the effect 
of triamcinolone acetonide injected into the SCS by a microneedle and compared it with 
that injected intravitreally when treating endotoxin-induced posterior inflammation in 
a porcine eye model. The animals with the induced inflammation were treated by 
suprachoroidal injection of 0.2 mg of triamcinolone acetonide and intravitreal injection 
of 2.0 mg of Triesence® (a commercially available triamcinolone acetonide). 
Triamcinolone acetonide was diluted using a vehicle to provide (0.2 mg/100 µL) for 
suprachoroidal injection and (2.0 mg/100 µL) for intravitreal injection.  They indicated 
that microneedle injection of triamcinolone acetonide is simple, effective, with a lower 
risk of infection or mechanical retinal damage relative to intravitreal injection [195].   
They also revealed that suprachoroidal and intravitreal administration were equally 
effective in improving the endotoxin-induced uveitis in the porcine model. In addition, 
no elevation of IOP was observed after microneedle SCS injection of triamcinolone 
acetonide. This indicated at least a 10-fold reduction in the effective dose of TA when 
administered through suprachoroidal injection due to targeted triamcinolone acetonide 
delivery [195]. 
 
4.4.2. Intracameral route 
Intracameral injection involves the local injection of drug substances into ocular 
cavities, bypassing the corneal barrier (Figure 3). It may be used to deliver antibiotics 
and corticosteroids directly to the aqueous humor [196]. This route of ocular drug 
delivery provides direct drug delivery to the anterior chamber, hence, less  of the drug 
is needed to achieve the desired effect with reduced side effects relative to topical and 
systemic drug administration [197]. 
Tan et al. [198] studied the efficacy of intracameral injection of dexamethasone 
(Surodex® 60 μg) and topical dexamethasone administration (0.1 % dexamethasone eye 
drops) for postoperative ocular inflammation after cataract surgery. On day 14 of 
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treatment, the inflammation assessment showed lower flare and cell values with 
intracameral Surodex®  treated group compared to those treated by topical 
dexamethasone eye drops [198].  
Dexamethasone, injected intracamerally for controlling postoperative inflammation 
after cataract surgery, provided a higher drug level with lower side effects including 
IOP elevation compared to those resulting from topical or systemic administration 
[197]. This is attributed to the localized low dose administration achieved by 
intracameral injection compared with topical and systemic administrations.  
The efficacy of intracameral injection of triamcinolone acetonide was studied by Wang 
et al.  [199] in a prospective randomized controlled trial. They observed that 
intracameral injection of triamcinolone acetonide effectively reduces the aqueous 
inflammation and improves the visual acuity after phacotrabeculectomy [199]. Simaroj 
et al.  [200] revealed that a single intracameral injection of triamcinolone acetonide (2 
mg in 0.1 ml) in combination with gentamycin (0.2 mg in 0.1 ml) could be used as an 
effective treatment of ocular inflammation following cataract surgery. No serious side 
effects or elevation in the IOP were reported one month following injection [200].  
However, there are certain adverse effects related to the intracameral route of ocular 
drug delivery, especially with sustained-release implants. These include tissue 
hemorrhage, prolapse of the iris, surgical hyphema and possibility of implant migration 
[197]. Also, there is an increased risk of toxic anterior segment syndrome with 
intravitreal injections, which involves postoperative inflammatory response as a result 
of the injection of noninfectious substances into the anterior chamber [197, 201]. 
Despite such limitations, an intracamerally injected biodegradable implant for sustained 
reduction of intraocular pressure in patients with open angle glaucoma or ocular 
hypertension has been approved by the US FDA during 2020, suggesting adequate risk-
benefit ratio. 
 
4.4.3. Intravitreal route 
Intravitreal injections of corticosteroids have been progressively used instead of 
systemic administration for the treatment of a number of diseases that affect the 
posterior segment of the eye including macular edema and noninfectious posterior 
uveitis. Unlike systemic administration, which requires milligram doses each day, a 
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sub-milligram dose of corticosteroid is sufficient in slow-release systems administered 
intravitreally over durations of 0.5 to 3 years. This is because the intravitreal injection 
bypasses the blood–ocular barrier and other barriers related to topical administration by 
direct localization of the drug in the vitreous, thereby achieving therapeutic levels in 
the eye, minimizing both drug dose needed  as well as systemic adverse effects (Figure 
3) [202]. The maximum volume injected intravitreally is limited to 100 µl [203] and  
half-life in the vitreous is a few hours. Consequently, repeated monthly injections, 
sometimes life long, are required for sustained drug effects and improving therapeutic 
outcomes [203]. A key goal of drug delivery research is to prolong vitreal residence 
time of drugs using different drug forms or slow release systems since repeated 
intraocular injections increase the risk of injury and infection to the eye.  
Vitreal half-life of drugs depends on drug lipophilicity, solubility, and molecular 
weight. Smaller molecules can be distributed and cleared more rapidly than larger ones 
[204]. Further, the vitreal half-life generally increases with an increase in drug 
hydrophilicity and molecular weight [205]. Injection of drug suspensions as opposed to 
a solution form of the drug is one approach to prolong the apparent vitreal half-life from 
a few hours to several days. Durairaj et al. [205], proposed dose number as the ratio of 
the drug dose to vitreal solubility, with a half-life of drug suspensions increasing as the 
dose number increases. This study also indicated that the presence of pigment in the 
eye increases the half-life of a drug molecule. Relationship between vitreal half-life and 
dose number is evident in the greater persistence of triamcinolone acetonide as the drug 
dose is increased. When triamcinolone acetonide dose was increased from 4 to 24 mg, 
the drug was present in the aqueous humor at 6 months post-dosing. This could be due 
to inefficient dissolution or dose-limited dissolution of triamcinolone acetonide in the 
vitreous humor [206]. Thus, drug solubility is a critical factor in increasing the mean 
residence time in the vitreous humor, with the apparent half-life increasing with a 
decrease in drug solubility or dose in the vitreous humor. The water-soluble 
dexamethasone sodium phosphate was found to have a shorter half-life (about three 
hours) within the vitreous humor, while the more lipophilic corticosteroid 
triamcinolone acetonide showed a longer residence time up to a few months [207, 208]. 
Triamcinolone acetonide, which is a synthetic corticosteroid that was formulated as an 
injectable suspension, can last in the vitreous for a much longer time than some others 
due to its lower water solubility [209].  
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Commercially approved intraocular triamcinolone suspensions include Triesence® and 
Trivaris® [30]. Triesence® (aqueous suspension) provides 40 mg/ mL of TA and the 
vehicle is free from preservatives [210]. Trivaris® contains 80 mg/mL of TA in a 
hydrogel (HYLADUR) in a preservative-free vehicle [211]. These suspensions were 
approved for the treatment of ocular inflammation that do not respond to topical 
corticosteroid administration [30]. Interestingly, both Triesence® and Trivaris® 
prolonged corticosteroid activity mainly based on their inherent lipophilicity and low 
solubility rather than the excipients or polymers used in the formulations [212]. 
Vitreal half-life also depends on the health of the vitreous humor. Beer et al. [206] 
studied the pharmacokinetics of triamcinolone acetonide after intravitreal injection of 
4 mg dose in vitrectomized and non-vitrectomized human eyes. They revealed that the 
elimination half-life was 18.6 days and 3.2 days in non-vitrectomized and vitrectomized 
eyes, respectively. Thus, the health of the vitreous humor is expected to play a role in 
drug disposition.  
Since a key goal of ocular corticosteroid therapy is to maximize the efficacy and to 
minimize the well-known adverse effects induced by corticosteroids and also to avoid 
the related systemic adverse effects, minimizing the exposure of the trabecular 
meshwork to corticosteroids by using low dose and posterior positioning of an 
intraocular implant could reduce the corticosteroid-induced local side effects, while 
simultaneously reducing the risk of systemic side effects [30, 213]. There are a number 
of corticosteroid implants with long-acting and slow-release properties that offer 
several advantages over topical and systemic administration. This is because the 
corticosteroids intraocular implants can bypass the blood-ocular barriers, require ultra-
low doses and avoid adverse effects associated with the systemic therapy.  
The implants reduce the risk associated with repeated intraocular injections. This would 
be of great benefit in the case of drugs that may be highly toxic when administered 
systemically [214]. Three common members (dexamethasone, fluocinolone acetonide 
and triamcinolone acetonide) of the corticosteroid family with different structures and 
pharmacokinetic properties has gained regulatory approval as intraocular implants for 
various ocular inflammatory conditions (Table 3).  
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Dexamethasone is relatively less potent and more water-soluble (0.16 mg/ml) [38] than 
both triamcinolone acetonide (21 µg/ml) [59] and fluocinolone acetonide (0.05 mg/ml) 
[64].  
Dexamethasone is formulated in a slow-release implantable delivery system in order to 
sustain therapeutic doses in the eye and commercially known as the intravitreal implant 
Ozurdex® [6]. Ozurdex® is the first commercially available implantable device of 
dexamethasone which was approved by the FDA in 2009 for the treatment of macular 
edema [6]. It contains dexamethasone which is incorporated into a biodegradable 
polymer, poly(lactic-co-glycolic) acid (PLGA). Ozurdex® was implanted intravitreally 
under sterile conditions for slow release of dexamethasone over 6 months into vitreous 
and diffuse into the target tissue of the choroid for treatment of uveitis [28].  
Pharmacokinetics of intravitreally injected Ozurdex® were studied in an animal model. 
Following bilateral Ozurdex® implantation in 34 male monkeys, the results showed a 
higher rate of initial drug release during the first two months followed by a prolonged 
low level of release and dexamethasone level was below the limit of detection after 6 
months [215]. A more recently approved dexamethasone-based slow release system is 
DEXYCU®. It was approved in 2018 for postoperative inflammation treatment and is 
based on an injectable sustained and bioerodible ocular delivery system (verisome™) 
[216]. DEXYCU® 9% intraocular suspension is dexamethasone suspension which is 
intracamerally injected as a single dose (50 μl) .The injected DEXYCU® has the ability 
to transform into small spheres at the injection site and these spheres are gradually 
degraded to release  dexamethasone for up to 3 weeks for treatment of post-operative 
inflammation after cataract surgeries [216, 217] 
Fluocinolone acetonide is a more potent corticosteroid with slightly higher water 
solubility compared to triamcinolone acetonide. Fluocinolone acetonide has three 
approved intravitreal implants: Retisert® and Iluvien® and Yutiq®. Retisert® [218] has 
the fluocinolone acetonide surrounded by a polyvinyl acetate/silicone thin layer fixed 
onto a structural base.  
Fluocinolone acetonide was approved by FDA in 2005. It is implanted surgically into 
the posterior segment of the eye for chronic noninfectious uveitis treatment. 
Pharmacokinetic studies showed a near zero-order drug delivery. The vitreous 
concentration was relatively constant following 2 hours implantation and lasted for one 
33 
 
year after vitreous implantation also the fluocinolone acetonide plasma level was under 
the detection limit at all times [219].  
 Iluvien® is the only fluocinolone acetonide implant that has been approved by the FDA 
since September 2014 for the treatment of DME [220]. Similarly, a near zero-order 
release was observed following the intravitreal injection of Iluvien® [221]. Moreover, 
after fluocinolone acetonide intravitreal implantation in patients having DME, the 
loaded drug was found to be released in a sustained manner into the aqueous and 
vitreous humor over 3 years. The steady-state fluocinolone acetonide aqueous 
concentration was in the range of  0.5-1.0 ng/ml for 6-9 months and the concentrations 
were constant between 1-3 year where the mean peak concentration was about 0.6 
ng/ml at 3 years with detectable fluocinolone acetonide aqueous concentration up to 3 
years [222]. Unfortunately, patients receiving fluocinolone acetonide implants were 
found to be at higher risk of developing elevated IOP [223]. Interestingly, during late 
2018, the FDA approved YUTIQTM (non-bioerodible intravitreal micro-insert) for 
sustained delivery of fluocinolone acetonide (0.18 mg) with linear sustained release 
kinetics up to 3 years for the treatment of chronic non-infectious uveitis [224].   
After intravitreal drug injection, elimination of the injected drug can occur through the 
anterior route via the aqueous humor turnover or through the posterior route via 
penetration of the retina and vascular barriers in the back of the eye [92, 225]. Literature 
reports indicate that  diabetic retinopathy can be improved by intravitreal injection of 
dexamethasone in animal models [226]. This is probably due to the lipophilic nature of 
dexamethasone and ready access of the drug to the retinal tissue. 
For intravitreally injected nanoparticles, the surface charge influences their vitreous 
mobility. Peeters et al. [227] reported that the intravitreally injected polystyrene 
nanospheres showed restricted mobility in the vitreous as a result of their adherence to 
the collagen fibers. However, the attachment of polyethylene glycol to their surfaces 
prevented their adherence to t collagen and consequently allowed improved particle 
movement in the vitreous [227]. 
The complications of intravitreal corticosteroids injection are commonly divided into 
two main groups firstly, corticosteroids-related side effects such as elevated IOP and 
cataract formation. Secondly, side effects related to injection such as vitreous 
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hemorrhage, detachment of the retina, infectious endophthalmitis and non-infectious 
endophthalmitis [197, 228].  
Studies of intraocular implants revealed that corticosteroid-induced IOP elevation was 
lower in the dexamethasone implant group, compared to the patients treated with 
fluocinolone acetonide and or triamcinolone acetonide implants. Corticosteroid-
induced IOP elevation was observed in 11% of individuals following intravitreal 
implantation of 0.35 mg of dexamethasone. However, 32 and 66 % of individuals 
developed elevated IOP after intravitreal implantation of 4 mg triamcinolone acetonide 
and 0.59 mg of fluocinolone acetonide, respectively [65]. This may be due to the 
lipophilicity of dexamethasone, which is lower than that of triamcinolone acetonide and 
fluocinolone acetonide, resulting in less binding to the ocular tissues of the trabecular 
meshwork and the human lens reducing the risk of elevation of IOP and cataract 
development  [229]. Nevertheless, intraocular implants have local side effects (Table 



































































5. Ophthalmic adverse effects of corticosteroids  
Ophthalmic corticosteroids adversely affect different parts of the human eye, from the 
outer eye layers of the eye, mainly the cornea to the orbital fat as well as the optic nerve. 
The two major (> 10% of the treated population) ocular side effects include elevation 
of IOP and cataract [6, 220]. The side effects of corticosteroids can be classified as 
those caused by systemic administration, intraocular injection, implants, or from topical 
administration [61, 233]. 
Table 4 summarizes the most common ocular side effects of corticosteroids following 
different methods of dosing. 
 
 
Table 4 Summary of the most common adverse effects associated with the 
administration of corticosteroids via different routes. 
Topical administration Systemic administration Periocular injection Intraocular injection 
 
• Increased IOP [234]. 
• Posterior subcapsular 
cataract [235] 
• Increased IOP [234]. 
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• Decreased resistance 
to infection [16]. 
• Delayed corneal and 
scleral wounds healing 
[236]. 
• Mydriasis [237]. 
• Ptosis [238] 
• Retinal embolic 
phenomenon [16] 
• Optic atrophy [16]. 
 
• Papilledema [240]. 
• Subconjunctival or 
retinal hemorrhages 
[16]. 
• Central serous 
chorioretinopathy 
[241]. 
• Retinal embolic 
phenomenon 





• Cataract formation 
[174] 
 
Injection related side 
effects 
 
Injection related side 
effects 
 
• Ocular pain [247] 
• Ptosis [174] 
• Subconjunctival 
hemorrhage [248] 
• Globe perforation 
[249] 
• Retrobulbar 
hemorrhage [250].  
 
• Ocular pain [243] 
• Decrease visual acuity 
[16] 
• Retinal hemorrhages 
[251]. 
• Retinal degeneration 
[171]. 
• Periocular atrophy or 
fibrosis [252]. 
• Endophthalmitis [239]. 
• Ocular infection [253]. 
• Vitreous hemorrhage 
[254]. 









5.1. Corticosteroid-induced IOP elevation (ocular hypertension) 
A major problematic complication of glucocorticoid therapy is the rise in the IOP, 
which at sufficient elevation and duration without treatment may lead to impairment of 
the optic nerve, resulting in corticosteroid-induced glaucoma [14]. This can occur when 
corticosteroids are administered exogenously through all modes of administration  
(topical, periocular, intravitreal, or systemic administration) [255-258] and the rise in 
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IOP happens after repeated doses of conventional corticosteroid ophthalmic eye drops 
[105]. Interestingly, certain health conditions, such as Cushing’s syndrome, wherein 
endogenous production of corticosteroids is elevated, could increase IOP [259].  
Patients with elevated IOP may have symptoms of headache, eye pain and reduced 
visual acuity [260]. The first report of increased IOP induced by locally administered 
corticosteroids was described by Francois [14]. Armaly and Becker [261-263] 
classified populations into low, intermediate and high responders depending on IOP 
elevation following topical administration of corticosteroids and related it to the 
inheritance of primary open-angle glaucoma (POAG) [261].  
The elevated IOP and glaucoma development more probably occur in corticosteroid-
responsive individuals than in those non-responsive. It is found that about 18% to 36% 
of the general population had a moderate increase of 5 mm Hg or more in IOP following 
topical corticosteroid administration [121, 264]. However, 46 to 92% of patients with 
POAG and 5 to 6% of the general population can show a significant and potentially 
damaging increase in IOP after topical corticosteroid administration [264-266]. This 
indicates that patients with POAG and glaucoma suspects show a higher incidence of 
IOP elevation following topical corticosteroid administration [261].  
 
5.1.1. Mechanism of corticosteroid-induced IOP elevation 
The exact mechanism by which corticosteroids induce an elevation in IOP remains 
inconclusive. Trabecular meshwork cells, which normally drain approximately 90% of 
the aqueous humor and contain a great number of corticosteroid receptors, have been 
hypothesized to have a key role in the incidence of corticosteroid-induced IOP elevation 
[229, 267, 268]. Figure 4 showed the proposed mechanisms of corticosteroid-induced 
IOP elevation. 
The administered corticosteroids could enter the trabecular meshwork cells, leading to 
engagement of corticosteroid receptors and changes in the expression of trabecular 
meshwork genes [269, 270]. It is assumed that these changes in gene expression result 
in alterations in the extracellular matrix and amorphous granular material accumulated 
below the endothelial lining of the canal of Schlemm, thereby increasing the thickness 
of the trabecular beams and resulting in a decrease in the intertrabecular spaces. All 
these changes may increase the resistance of aqueous flow and elevate IOP [264, 267].  
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An alternative theory assumes that the elevation of IOP results from the stabilization of 
lysosomal membrane enzymes by the administered corticosteroids and inhibition of 
lysosomal enzymes release [271]. This results in decreasing the degradation of 
glycosaminoglycans (GAG) by these enzymes and consequent accumulation of GAG 
in the polymerized form in the trabecular meshwork, thereby decreasing aqueous 
outflow and elevating IOP [16, 272].  
A third explanation that has been proposed makes the assumption that corticosteroids 
cause swelling of the collagen strands of the trabecular meshwork by increasing the 
water-binding capacity of the mucopolysaccharides and decreasing the trabecular 
meshwork phagocytic activity, ultimately resulting in accumulation of cellular debris,  






Figure 4 Graphical illustration of proposed mechanisms of corticosteroid-induced 
elevation of intraocular pressure, modified from [274]  
 
5.1.2. Factors affecting corticosteroid-induced IOP elevation 
5.1.2.1. Effect of age 
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The elevation of IOP as a result of corticosteroid administration is found to be age-
dependent. Many reports revealed that children are greater steroidal responders 
compared to adults [105, 275-277]. It has been shown that children below the age of 10 
were susceptible to developing rapid IOP elevation following topical corticosteroid 
administration. In patients aged between 7 to 21 years with inflammatory bowel disease 
and receiving oral corticosteroids, 31.5% were reported to be corticosteroid responders, 
with a raised IOP of at least 6 mmHg greater than that in adults [234, 276, 277]. For 
more discussion and examples on the elevation of IOP with  age in response to 
corticosteroids, the reader is referred to the review published by Jones and Rhee [105] 
.  
5.1.2.2. Effect of type and properties of administered corticosteroids 
 
Elevation of IOP induced by corticosteroid administration seems to be closely linked 
to the potency, dose, and frequency of administration as well as the duration of therapy 
[16]. The less potent agents require a longer duration of therapy to produce increased 
IOP and the elevation is not as high as those induced by more potent agents [149]. Table 
5 represents the relative anti-inflammatory properties of certain members of 
corticosteroids used for ocular diseases. The higher elevation in IOP with more potent 
agents is likely due to the higher affinity to glucocorticoids receptors located on cells 
of the trabecular meshwork.  
Following 6 weeks of topical corticosteroid treatment at a fixed concentration of 0.1%, 
the average increase in IOP for dexamethasone, fluorometholone, and medrysone is 
approximately 63%, 35% and 8%, respectively. This trend could be attributed to the 
difference in potency of these agents [278]. The more potent corticosteroids result in 
corticosteroid-induced IOP elevation within a few weeks of treatment while less potent 
members may provoke IOP elevation within months [279]. Infrequently, potent topical 
corticosteroids may induce acute elevation of IOP within hours or days of 
administration [280]. The potency of administered corticosteroids and consequently 
their effect on IOP depends on many factors such as drug structure and physicochemical 
properties [281]. It is found that only steroids that can penetrate into the anterior 
chamber induce elevated IOP. For example, medrysone (1 %) which is hydrophilic and 
with low potency, caused a 1.0 mm Hg increase in IOP, while more potent 
corticosteroids such as prednisolone acetate (1%) and dexamethasone acetate (0.1%), 
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which are lipophilic prodrugs, were found to cause a 10 and 22 mm Hg increase in IOP, 
respectively [282, 283]. This is attributed in part to their enhanced corneal permeability 
as a result of the increased lipophilicity.  
Difluprednate (difluoroprednisolone butyrate acetate), which is a prednisolone 
derivative with high potency due to its increased lipophilicity compared to 
prednisolone, was found to cause elevation of IOP that was two-fold greater than 
prednisolone when used in postoperative inflammation treatment [284].  
In addition, there is a strong relationship between corticosteroid-induced IOP and the 
dose of administered agents. Tripathi et al. [234] found that for each 10 mg increase in 
a daily dose of prednisolone there was a 1.4 mm Hg elevation in the mean IOP [234].  
In addition, the IOP is affected by different forms of the same drug.  For instance, 
triamcinolone acetonide (minimally water-soluble form) was found to produce 
sustained, elevated IOP for 6 months following sub-tenon injection. However,  its 
diacetate form (moderately water-soluble form) had a less sustained effect on IOP [285, 
286]. Generally, the increase of IOP has been reported to happen over weeks and in 




Table 5 Relative anti-inflammatory properties of certain ocular corticosteroids [240, 
287, 288]. 
Corticosteroids agents Relative anti-inflammatory potency 
Hydrocortisone 1 
Prednisolone/prednisone 4 
Methyl prednisone 5 
Triamcinolone 5 
Fluocinolone acetonide 25 
Betamethasone 25 





5.1.2.3. Effect of concurrent diseases and the race 
The prevalence of corticosteroid-induced IOP elevation was found to be affected by the 
concurrent disease. Patients with type-1 diabetes mellitus [289],  high myopia [290] 
and men with connective tissue diseases [291] are at increased risk of steroid-induced 
IOP elevation. A positive relationship exists between the development of open-angle 
glaucoma and the incidence of systemic hypertension and migraine [292]. Patients with 
POAG are at increased risk for the rise of IOP when treated with corticosteroids for 
ocular inflammatory conditions. For example, topical dexamethasone 0.1% eye drops 
for one month led to an increase in IOP by > 6 mmHg in 90% of treated patients with 
coexisting POAG [105]. 
Patients with excess production of endogenous corticosteroids, such as in Cushing’s 
syndrome secondary to adrenal adenoma, carcinoma or adrenal hyperplasia, are found 
to be more susceptible to corticosteroid-induced IOP elevation, but the elevated IOP of 
such patients usually returns to its normal levels following adrenalectomy [293, 294]. 
Corticosteroids (glucocorticoids and mineralocorticoids) and cortisol have been found 
to be a constant component of the aqueous humor and have been measured by isotope 
dilution techniques and radioimmunoassay; their concentrations in the aqueous humor 
are lower than the plasma level [295]. It was found that the concentration of cortisol in 
the aqueous humor and plasma was elevated in patients suffering from various eye 
diseases. This indicates the possible role of these endogenous hormones in the 
development of some eye diseases, especially those characterized by the elevated IOP 
[296]. Furthermore, the Baltimore study (Baltimore Eye Survey) revealed that black 
Americans are 3 to 4 times more susceptible to the incidence of POAG than  white 
Americans [297]. 
 
5.1.2.4. Non-ocular routes of administration of corticosteroids can potentially 
harm the eye 
Corticosteroids are commonly administered as nasal sprays or inhalations for treatment 
of different respiratory disorders including allergic rhinitis and asthma. Patients 
receiving high doses of inhaled corticosteroids for prolonged durations are at risk of 
corticosteroid-induced IOP elevation [14, 298]. 
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Spiliotopoulos et al. [299] studied the effect of inhaled corticosteroids on the IOP. An 
aerosol nasal spray comprising 120 µg tramazoline hydrochloride and 20 µg 
dexamethasone was inhaled by 54 patients, once daily. Results showed that no change 
in the IOP was reported in about 66.7 % of patients, while 11.1, 9.3, 5.6, and 7.4 % had 
an IOP elevation of 1, 2, 3 and 4  mmHg, respectively [299]. Inhaled and nasal steroids 
for 3 months have been associated with increased risk of elevation of IOP [257, 298]. 
Also, topical skin administration of corticosteroids is widely used for the treatment of 
various dermatological diseases such as vitiligo, acne vulgaris, and atopic dermatitis. 
Long term topical use of corticosteroid ointment has been reported to cause open-angle 
glaucoma [300]. Also, cosmetic products (facial lotions and creams) with 
corticosteroids components, may induce elevated IOP after application to the periocular 
region for a prolonged time [300, 301]. 
 
5.1.2.5. Effect of administered pharmaceutical ingredients and formulations  
Ophthalmic formulations that were able to increase the corneal contact time as 
microsuspensions [161], gels and viscous formulations [302] can increase exposure 
duration or the corneal permeation and raise the concentrations/exposure of loaded 
corticosteroids in the aqueous humor. Additives such as cyclodextrin polymer leading 
to enhancement of corticosteroid solubility can consequently increase corneal 
permeability. Topical administration of an aqueous drop containing dexamethasone-
cyclodextrin inclusion complexes increased the aqueous humor concentration of 
dexamethasone by approximately 2.6 times in the AUC when compared to the marketed 
available solution eye drop of 0.1% dexamethasone alcohol following 1.9 h 
administration [120]. 
For intraocular corticosteroids implants dosage form, elevated IOP remains a common 
side effect which appears to mirror the drug release/concentration in the eye since it 
returns to the normal baseline when the drug is depleted from the implanted devices 
[303]. Ozurdex® (dexamethasone) implant resulted in a temporary elevation in IOP 
[28]. Not only the type of implanted corticosteroid but also the dose and position of the 
implant have a great effect on the induced IOP elevation. As previously discussed, 
minimizing the exposure of trabecular meshwork to corticosteroids by posterior 
positioning of the implanted devices leads to lower elevation in IOP. This was observed 
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with fluocinolone acetonide implants as Iluvien® and Retisert®.  Iluvien® (0.19 mg) led 
to a 7-fold more lowering in elevation of IOP than Retisert® (0.59 mg). This could also 
be attributed in part to the markedly lower dose of Iluvien®  than Retisert® implant [30].  
Nano-sized drug delivery systems have been recorded as playing a role in controlling 
the resultant elevated IOP of the administered corticosteroids. Gaafer et al. [50] studied 
the effects of different forms of prednisolone: prednisolone acetate (a less soluble form) 
and prednisolone Na phosphate (a soluble form) on elevated IOP. Their results revealed 
that both prednisolone Na phosphate solution and prednisolone acetate suspension 
showed fast absorption with a steep elimination phase compared with prolonged and 
controlled absorption recorded for nano-sized elastic niosomes embodying alcohol 
(ethoniosomes) and prednisolone acetate or prednisolone Na phosphate.  This resulted 
in a sharp and rapid increase in IOP for the suspension and solution dosage form 
compared to a controlled prolonged increase IOP and a lower ΔIOP with ethoniosomes 
[50]. 
 
5.2.  Corticosteroid-induced cataract formation 
A major side effect due to prolonged use of corticosteroids is the increased risk of 
development of cataracts [304]. Ageing is the major risk factor for cataract, the causes 
of which are considered to include an increase in oxidative stress and post-translational 
modification of the lens crysatllins that lead to aggregation and insolubilization [305].    
Corticosteroid induced cataract formation was first reported by Black and colleagues, 
whose findings showed the development of cataract in 39 % of rheumatic patients who 
had been on systemic treatment with corticosteroids [262]. The pathogenesis of 
corticosteroid-induced cataract has led to a number of hypotheses including water 
accumulation within lens fiber cells, lens protein aggregation due to inhibition of Na + 
/K +  pump in the single epithelial layer of the human lens [306], and corticosteroid 
binding to lens proteins leading to the development of lysine-ketosteroids, covalent 
adducts, and lens opacities [307].  
Figure 5 shows post-translational modifications of lens crystallins induced by the 
corticosteroid dexamethasone. This involves the reaction of the nucleophilic amino 
group in the lysine residues of lens proteins with the steroidal C20 keto group, resulting 
in the formation of a Schiff base [308]. Heyns rearrangement of the formed Schiff base 
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leads to the formation of a stable ketoamine adduct. The resultant steroidal-protein 
adducts, with their large molecular weight, could alter the normal structure of lens 
proteins, leading to cataract formation [309]. This hypothesis is supported by in vitro 
observation of rabbit lens opacification following exposure to corticosteroids. The 
resultant opacification was similar to those formed in humans [310, 311].   
Other theories include increased plasma and aqueous humor glucose level, inhibition 
of glucose-6-phosphate-dehydrogenase enzymes, and inhibition of RNA synthesis 
[312]. The incidence of corticosteroid-induced cataract increases with increasing dose 
and duration of treatment and individual variations in susceptibility [313]. Cataract 
formation may result from topical, intraocular, or systemic administration of 
corticosteroids. According to a population-based study, inhaled budesonide or 
beclomethasone (1000 µg/d) for over  2 years led to three times increase in the risk of 
cataract surgery [314]. The risk of development of corticosteroid-induced cataracts is 
not fully understood but it may be related to the intraocular penetration of 
corticosteroids and the duration of therapy.  
It has been noticed that 0.1% fluorometholone has a low capacity for elevation of the 
IOP, with poor penetration into intraocular tissues [315]; however, it has been reported 
to induce cataract formation after a period of 4 months application [315]. The 
development of cataract may still occur, even if the administered corticosteroid dose is 
decreased; however, drug discontinuation may prevent further damage to crystallins 
and cataract formation or it may reverse the lens opacification [316].  
Interestingly, animal studies showed that tocopherol (vitamin E) administered topically 
or systemically is useful as a prophylactic treatment against steroid-induced cataract in 
animal models [317]. More recently, sacrificing glycating agents such as L-carnosine 
could spare native crystallins from Heyns rearrangement by interacting with carbonyl 
groups instead of crystallins and hence, they act as prophylactic agents against 
corticosteroid-induced cataract formation [318]. However, further clinical studies are 
















 Figure 5 Corticosteroid-induced post-translational modifications of lens proteins 
(crystallins). Terminal free amino acids of lysine residues interact with carbonyl 
(C=O) groups of corticosteroid and forms Heyns rearrangement leading to crystallin 




6. Approaches to avoid and minimize corticosteroid-induced ocular 
complications 
General principles that should be followed with corticosteroid administration to prevent 
and/or minimize the development of corticosteroid-induced ocular complications are as 
follows: a) ophthalmic examinations should be conducted every 6 months for patients 
receiving long term treatment with ocular corticosteroids;  b) appropriate dosage forms 
and routes of administration should be carefully selected according to the disease to be 
treated [27, 242]; the healthcare provider should take into account the risk/ benefit ratio 
when selecting specific drugs, their dose, and duration [242, 320]. c) Targeted therapy 
is preferred more than generalized therapy [242] and in some cases, sustained-release 
drug products may be more appropriate for reducing the frequency of visits, injections 
and systemic side effects [321]. Long-acting implantable corticosteroids such as 
Ozurdex® and Retisert® can elevate IOP and induce cataract formation. Further studies 
are needed to optimize such corticosteroid implants in terms of the dose, duration of 
the activity, and placement. 
Other suggestions have been discussed elsewhere such as concomitant administration 
of topical antiglaucomic agents during corticosteroids therapy for life-long vision-
threatening ocular diseases such as AMD and use of steroid receptor antagonists such 
as mifepristone [14]. However, none of these approaches were approved for clinical use 
and further clinical studies are needed.  
Nonsteroidal anti-inflammatory drugs (NSAIDs) could serve as potential alternatives 
to corticosteroids in some ophthalmic inflammatory conditions. They are not 
accompanied by the risk of elevated IOP or increased susceptibility to infection [322]. 
For example, a double-blind parallel comparison of dexamethasone  with the NSAID 
ketorolac demonstrated that ketorolac has an effect similar to dexamethasone  in 
decreasing the postoperative inflammation after cataract surgery [323].  
Similarly, the anti-inflammatory effect of diclofenac sodium was comparable to that of 
dexamethasone sodium phosphate at equal concentrations (0.1%) [324]. The results 
showed similar reduction in the aqueous cell counts or equivalent anti-inflammatory 
efficacy [324]. Ocular side effects reported with NSAIDs include burning and stinging 
to more serious ocular complications like corneal erosion and corneal ulceration and 
melting [325, 326]. 
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Immunosuppressants are another drug class that can be used as an alternative to 
corticosteroids for treatment of ocular inflammatory conditions without causing the 
sight impairment side effects of corticosteroids (ocular hypertension and cataract). This 
include cyclosporine which is an immunosuppressant drug is available as an ophthalmic 
emulsion (Restasis®) for treatment of severe dry eye conditions and other inflammatory 
surface eye diseases. Tacrolimus (0.1%) eye drops is another immunosuppressant agent 
used off-label by ophthalmologists to treat meibomian gland inflammation and allergic 
conjunctivitis [327]. 
 
7.  Future perspectives 
Corticosteroids, members of a class of highly potent ophthalmic anti-inflammatory 
agents, are used in treating inflammatory conditions affecting multiple tissue targets 
within the ocular surface, anterior and posterior segments of the eye. A variety of 
dosage forms are available for ophthalmic use of corticosteroids, including solutions, 
suspensions, emulsions, ointments, gels, puncta plug, biodegradable implant for 
injection (preformed as well as in situ forming), and non-degradable implants for 
injection. Additionally, iontophoretic delivery systems are currently being evaluated.  
Iontophoretic drug delivery us currently being explored in clinical trials. This approach 
to enhance ocular drug delivery was summarized by Eljarrat-Binstock and Domb [328]. 
This enhances the delivery of administered drugs based on their charge, using a low 
electric current. When an ionizable drug substance is subjected to an electrical current, 
it may result in increased flux across biological membranes due to electron repulsion 
or electroosmotic flow [329]. Interestingly, this technology is currently under clinical 
development for corticosteroid delivery. The EyeGate II delivery system (EGDS), an 
innovative ocular iontophoresis delivery system, has been developed to maintain drug 
levels in the anterior and posterior eye segments [330]. The EGDS has been studied for 
the delivery of dexamethasone sodium phosphate (EGP 437) for the treatment of 
anterior uveitis and dry eye. The outcomes of clinical studies revealed the safety and 
efficacy of the product with lower elevation in IOP; consequently, it may provide a 
potential alternative for the conventional delivery systems [331]. However, wide patient 
acceptance of electrical current based delivery of drugs has yet to be established for a 
sensitive organ like the eye. A more patient friendly approach is Dextenza® punctual 
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inserts/plugs of dexamethasone that is inserted non-invasively into the punctum (an 
opening in the eye lid through which tear fluid drain) of the affected eye after cataract 
surgeries for treating pain and inflammation post-cataract surgery. Dextenza® punctual 
inserts/plugs can provide sustained release of the corticosteroid drug to the ocular 
surface for up to 4 weeks [332].   
Due to their potency, very low doses of corticosteroids are needed for treating eye 
diseases locally, relative to their systemic doses. This minimizes systemic side effects. 
Although the use of corticosteroids for the treatment of eye diseases is widespread and 
beneficial, the formulation of novel approaches for corticosteroid usage with minimal 
local side effects is much needed. Key local side effects are intraocular pressure 
elevation and cataract formation.  
A major approach to minimize the side effects of corticosteroids in ophthalmic use is 
based on retrometabolic drug design, which was first introduced in 1970 by Bodor and 
colleagues [333]. This technique is based on developing corticosteroids that will 
produce their desired therapeutic effects and quickly biotransformed into inactive 
moieties in order to eliminate undesired side effects. One promising synthetic 
corticosteroid designed by the retrometabolic technique is loteprednol etabonate. It is 
commonly known as a soft drug and belongs to a unique class of corticosteroids that 
were designed to maintain effective anti-inflammatory activity while reducing the risk 
related to this group of medication, especially that of induced IOP elevation and cataract 
formation [309].  It is designed with two ester linkages at 17α- and 17 β-positions. It 
loses its corticosteroid activity upon hydrolysis of either ester bond in cornea and 
aqueous humor, producing inactive metabolites [334, 335];. Many clinical studies have 
revealed the effectiveness of loteprednol etabonate in numerous ocular inflammatory 
conditions including giant papillary conjunctivitis [336], allergic conjunctivitis [337], 
anterior uveitis [338], keratoconjunctivitis [71], and postoperative inflammation [338]. 
Interestingly, the risk of elevation in IOP by loteprednol etabonate was found to be low 
(similar to that observed with the vehicle) and markedly lower than that observed with 
other corticosteroids, even in steroid responder patients [339]. Clinical studies were 
performed to estimate the efficacy of loteprednol etabonate 0.5% against prednisolone 
acetate 1.0% for controlling postoperative inflammation following cataract surgery. 
The results indicated that both loteprednol etabonate and prednisolone acetate were 
equivalent in the control of inflammation after cataract surgery. However, treatment 
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with loteprednol etabonate resulted in elevation in the IOP of approximately 60% of 
that produced by prednisolone acetate 1.0%. This study, however, was an acute study 
spanning 3 days. The product literature for 0.5% loteprednol etabonate indicates that it 
is slightly less effective in a 28-day study for treating acute anterior uveitis when 
compared to 1% prednisolone acetate (resolutions in 72% vs 87% of patients) with the 
incidence of 10 mm Hg or greater increase in IOP in 1% of the patients with loteprednol 
etabonate vs. 6% for prednisolone acetate. The product literature still carries the 
warning of the potential for cataract and IOP elevation. Ophthalmic suspensions of 
0.5% and 0.2% were the first commercial formulations for loteprednol etabonate 
approved by the FDA in 1998. Recently, many formulations have been developed as 
suspensions, ointments and gels [338, 340, 341]. 
 In addition to drug design by retrometabolic approaches (e.g., loteprednol 
etabonate), development of new corticosteroids with therapeutics benefits that can 
outweigh side effects has been an endeavour. For example, corticosteroids conjugated 
with glycine or formation of PEGylated corticosteroids (conjugation with polyethylene 
glycol) have been utilized to generate new members of corticosteroids with larger 
molecular weight and more hydrophilicity. Such approaches could undermine 
corticosteroids  lipophilicity and  cell permeability [83, 85].    
 
Thirdly, alternative choices to corticosteroids notably NSAIDS and other compounds 
are being investigated. NSAIDs have been utilized in ophthalmology for the treatment 
of inflammation, scleritis, and to protect from and treat cystoid macular oedema 
secondary to cataract surgery [342-345]. Recently many NSAIDs have become 
available and these could be alternatives to corticosteroids with fewer treatment-related 
serious ocular adverse reactions. Examples of NSAID include diclofenac, nepafenac, 
flurbiprofen, ketorolac and suprofen with anti-inflammatory activity similar to that of 
prednisolone acetate in certain cases [346-348]. It has been shown that flurbiprofen did 
not alter the IOP level in high responder patients [349]. In experimental studies, 
celecoxib, a nonsteroidal anti-inflammatory drug that is a specific inhibitor of COX-2, 
has been shown to be effective in minimizing vascular biochemical and pathological 
changes in the diabetic retina [350-352]. These could be alternatives to corticosteroids, 
especially in patients with a high risk of IOP elevation.  
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Cyclosporine and tacrolimus are not corticosteroids but show immunosuppressant 
effects. These two drugs have been used as topical emulsion and topical eye drops, 
respectively for treatment of various inflammatory diseases such as severe allergic 
conjunctivitis, keratoconjunctivitis sicca (severe dry eye), scleritis and anterior uveitis 
[353, 354]. Topical cyclosporine and tacrolimus are generally safe from typical sight 
impairing side effects of corticosteroids (cataract and ocular hypertension). Other less 
serious side effects reported for topical tacrolimus include transient burning and 
stinging and increased risk of ocular infection [353]. Ocular pain and burning are the 
most reported side effects for topical cyclosporine 0.05% emulsion [354]. These two 
drugs cyclosporine and tacrolimus can be considered potential alternatives to 





Ocular corticosteroids are amongst the most widely used medications for controlling 
ocular inflammatory conditions. They are administered using various routes of 
administration and different delivery systems. Topical ophthalmic dosage forms are 
commonly used for the treatment of diseases of the ocular surface and anterior segment; 
alternative delivery routes such as periocular, suprachoroidal and intravitreal routes are 
useful for drug delivery to the posterior segment of the eye. Although corticosteroids 
are potent and generally effective, they pose a significant risk of causing serious ocular 
adverse effects including cataract formation and elevated IOP. The severity of the 
corticosteroid associated side effects mainly relies on the potency of the administered 
corticosteroids, size of the dose, duration of therapy and the drug delivery route. Topical 
corticosteroids can induce rapid elevation of IOP within few hours postadminstration; 
on contrary, systemic corticosteroids administration requires high doses and prolonged 
treatment periods. Intraocular implants (Ozurdex®, Iluvien® and Retisert®) have greatly 
reduced systemic side effects but more chronic delivery with these systems raises the 
probability of incidence of cataracts and elevated IOP in majority of patients. 
Innovative ideas like Dextenza® plugs can provide prolonged treatment and the therapy 
can be terminated if the side effects escalated, by removing the corticosteroid plug from 
the administration site. NSAIDs could be useful alternatives for corticosteroids; 
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however, they are not as broad in their anti-inflammatory activity as corticosteroids. 
Future line of research would further study the mechanisms of corticosteroid-induced 
adverse effects at sustained ultralow levels vs. pulsatile sustained delivery.  
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